Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN), a clinical-stage company developing therapeutics for genetically driven neuromuscular diseases, has announced its upcoming participation in the Stifel 2025 Virtual CNS Forum. The company's management will engage in a fireside chat scheduled for Tuesday, March 18, 2025 at 4:00 p.m. ET.

Investors and interested parties can access the live webcast through the Investors & Media section of Dyne's website. The presentation recording will remain available for replay on the company's platform for 90 days following the event.

News Market Reaction – DYN

+4.61%

+4.61% Session move

In the trading session that priced this news, DYN gained 4.61%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 4:00 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contacts:

Investors
Mia Tobias
Dyne Therapeutics
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker
Dyne Therapeutics
snartker@dyne-tx.com
781-317-1938

FAQ

When is Dyne Therapeutics (DYN) presenting at the Stifel 2025 Virtual CNS Forum?

Dyne Therapeutics will present on Tuesday, March 18, 2025 at 4:00 p.m. ET.

How can investors watch Dyne Therapeutics' (DYN) Stifel CNS Forum presentation?

Investors can watch the live webcast through Dyne's website at investors.dyne-tx.com in the Investors & Media section.

How long will Dyne Therapeutics' (DYN) Stifel presentation replay be available?

The presentation replay will be accessible for 90 days following the event.

What is the focus area of Dyne Therapeutics (DYN)?

Dyne Therapeutics is a clinical-stage company developing life-transforming therapeutics for people with genetically driven neuromuscular diseases.